HIGHLIGHTS
- who: Elizabeth Sakach et al. from the Winship Cancer Institute, Emory University, Atlanta, GA, USA have published the paper: Trop-2 as a Therapeutic Target in Breast Cancer, in the Journal: Cancers 2022, 14, 5936. of /2022/
- what: The aim of the study is intracranial objective response rate and the secondary objectives are PFS, OS, and safety and tolerability of sacituzumab govitecan in this population. This two-part, open-label study was designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (capivasertib, oleclumab, T-DXd, dato-DXd) with or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.